Michael T Schuster

US Patent:

8527276, Sep 3, 2013

Filed:

Oct 25, 2012

Appl. No.:

13/660722

Inventors:

Andrew William Senior - New York City NY, US
Byungha Chun - Surrey, GB
Michael Schuster - Saratoga CA, US

Assignee:

Google Inc. - Mountain View CA

International Classification:

G10L 13/00

US Classification:

704259, 704258

Abstract:

A method and system for is disclosed for speech synthesis using deep neural networks. A neural network may be trained to map input phonetic transcriptions of training-time text strings into sequences of acoustic feature vectors, which yield predefined speech waveforms when processed by a signal generation module. The training-time text strings may correspond to written transcriptions of speech carried in the predefined speech waveforms. Subsequent to training, a run-time text string may be translated to a run-time phonetic transcription, which may include a run-time sequence of phonetic-context descriptors, each of which contains a phonetic speech unit, data indicating phonetic context, and data indicating time duration of the respective phonetic speech unit. The trained neural network may then map the run-time sequence of the phonetic-context descriptors to run-time predicted feature vectors, which may in turn be translated into synthesized speech by the signal generation module.

US Patent:

20110200612, Aug 18, 2011

Filed:

Jun 29, 2009

Appl. No.:

13/002229

Inventors:

Michael Schuster - New York NY, US
Silviu Itescu - Melbourne, Victoria, AU

International Classification:

A61K 39/395
A61K 35/00
A61K 35/12
A61K 35/44
A61K 35/28
A61P 27/02
A61P 9/00

US Classification:

4241581, 424 931, 424 937, 424 932

Abstract:

The present invention relates to methods of treating or preventing eye diseases, as well as angiogenesis-related diseases, by combination therapy involving administration of cells and a compound that disrupts VEGF-signalling.

US Patent:

20130171099, Jul 4, 2013

Filed:

Jul 4, 2011

Appl. No.:

13/808092

Inventors:

Silviu Itescu - Melbourne, AU
Michael David Schuster - New York NY, US

Assignee:

MESOBLAST, INC. - New York NY

International Classification:

A61K 35/28
A61K 45/06

US Classification:

424 852, 424 9371, 424577, 4241841, 4241301, 435377, 435325

Abstract:

A method for suppressing T cell activation which comprises contacting a cell population comprising T cells in vitro or ex viva with an effective amount of STRO-1 cells and/or soluble factors derived therefrom to suppress cell activation.

US Patent:

20130171113, Jul 4, 2013

Filed:

Jul 4, 2011

Appl. No.:

13/808093

Inventors:

Silviu Itescu - Melbourne, AU
Michael David Schuster - New York NY, US

Assignee:

MESOBLAST, INC. - New York NY

International Classification:

A61K 35/28

US Classification:

424 937

Abstract:

A method for preventing the development of or treating GvHD complications in a mammalian patient which comprises administering to the mammal a population of cells enriched for STRO-1cells and/or progeny thereof and/or soluble factors derived therefrom.

US Patent:

20210085723, Mar 25, 2021

Filed:

Oct 22, 2020

Appl. No.:

17/077698

Inventors:

- New York NY, US
Michael David Schuster - New York NY, US

Assignee:

Mesoblast, Inc. - New York NY

International Classification:

A61K 35/28
C12N 5/0775
A61P 37/02

Abstract:

A method for preventing the development of or treating GvHD complications in a mammalian patient which comprises administering to the mammal a population of cells enriched for STRO-1cells and/or progeny thereof and/or soluble factors derived therefrom.

US Patent:

20190030080, Jan 31, 2019

Filed:

Sep 14, 2018

Appl. No.:

16/131975

Inventors:

- New York NY, US
Michael David Schuster - New York NY, US

Assignee:

Mesoblast, Inc. - New York NY

International Classification:

A61K 35/28
C12N 5/0775
A61K 45/06
A61K 35/12

Abstract:

A method for preventing the development of or treating GvHD complications in a mammalian patient which comprises administering to the mammal a population of cells enriched for STRO-1cells and/or progeny thereof and/or soluble factors derived therefrom.

US Patent:

20170258846, Sep 14, 2017

Filed:

May 15, 2017

Appl. No.:

15/595719

Inventors:

Silviu Itescu - Melbourne, AU
Michael David Schuster - New York NY, US

Assignee:

Mesoblast, Inc. - New York NY

International Classification:

A61K 35/28
A61K 45/06
C12N 5/0775
A61K 35/12

Abstract:

A method for suppressing T cell activation which comprises contacting a cell population comprising T cells in vitro or ex vivo with an effective amount of STRO-1 cells and/or soluble factors derived therefrom to suppress T cell activation.

US Patent:

20160361363, Dec 15, 2016

Filed:

Feb 26, 2016

Appl. No.:

15/055221

Inventors:

Silviu Itescu - Melbourne, AU
Michael David Schuster - New York NY, US

Assignee:

Mesoblast, Inc. - New York NY

International Classification:

A61K 35/28
A61K 45/06

Abstract:

A method for preventing the development of or treating GvHD complications in a mammalian patient which comprises administering to the mammal a population of cells enriched for STRO-1cells and/or progeny thereof and/or soluble factors derived therefrom.